febit Announces Operational Restructuring
febit today announced a restructuring as a consequence of its strategic focus on bloodbased microRNA biomarker discovery…
febit today announced a restructuring as a consequence of its strategic focus on bloodbased microRNA biomarker discovery…
The latest study results that illustrate the high potential of microRNAs (miRNAs) as biomarkers for a broad range of dis…
Numerous experts in molecular diagnostics convened at the Second Workshop of the Biomarker Discovery Center (BDC, www.bd…
febit announced today the receipt of an EU patent, #EP 1 728 860B1, for its technology to synthesize minimal genomes.…
febit today announced that the company now offers whole genome sequencing services in Europe for a broad range of specie…
febit today announced that an updated version of the company's Geniom Biochip containing 58 new discovered sequences in…
febit today announced the launch of its HybSelector, a new instrument for high throughput targeted resequencing, at the…
The Molecular Genetics Core Facility (MGCF) at Children's Hospital Boston chose febit's HybSelect technology which will…
febit's HybSelect has been recognized as one of the winners of the "Top 10 Innovations of 2009" by The Scientist magazin…
The Cancer Genomic Microarray Facility at the Kimmel Cancer Center of the Thomas Jefferson University, Philadelphia, sel…